Objective To compare the clinical efficacy of Dapagliflozin and Linagliptin in the treatment of overweight or obese patients with type 2 diabetes mellitus(T2DM)with microalbuminuria.Methods A total of 58 patients diagnosed as overweight or obese with T2DM with microalbuminuria at the Seventh People′s Hospital of Nanhai District,Foshan City,Guangdong Province from April 2019 to April 2020.According to the random number table,they were divided into Dapagliflozin group and Linagliptin group,with 29 cases in each group.Both groups were treated with Metformin for basic treatment.Blood glucose related indexes,insulin resistance index,renal function related indexes and adverse reactions were compared between the two groups.Results The fasting blood glucose(FPG),2 h postprandial glucose(2 h PG)and glycosylated hemoglobin(GHb)after treatment in the two groups were lower than those before treatment,the FPG,2 h PG and GHb in the Dapagliflozin group after treatment were lower than those in the Linagliptin group,and the differences were statistically significant(P<0.05).After treatment,the insulin resistance index of the two groups was lower than that before treatment,and the insulin resistance index of the Dapagiflozin group was lower than that of the Linaliptin group,and the differences were statistically significant(P<0.05).Urinary microalbumin(UAlb),urine albumin/creatinine ratio(UACR),and serum creatinine(SCr)after treatment in the two groups were lower than those before treatment,the UAlb,UACR and SCr of the Dapagliflozin group after treatment were lower than those of the Linagliptin group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Dapagliflozin can effectively improve the blood sugar of overweight or obese patients with T2DM with microalbuminuria,lower their insulin resistance index and improve their renal function,and reduce the incidence of adverse reactions.